News

Grünenthal’s resiniferatoxin receives Breakthrough Therapy Designation from U.S. FDA for pain associated with osteoarthritis of the knee

by

Knee osteoarthritis is a progressive condition affecting over 360 million people worldwide and may have severe symptoms, including pain. Grünenthal is running a global Phase III programme to investigate the efficacy and safety of intra-articular injections of resiniferatoxin, a non-opioid therapy, in adults with pain associated with knee osteoarthritis. The U.S. Food and Drug Administration’s … Read more

Pharmaceutical Filtration Market to be Worth $21.96 Billion by 2030: Grand View Research, Inc.

by

SAN FRANCISCO, May 22, 2023 /PRNewswire/ — The global pharmaceutical filtration market size is estimated to reach USD 21.96 billion by 2030, registering a CAGR of 8.03% from 2023 to 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 8.03% from 2023 to … Read more

IDEAYA Announces IND Clearance Enabling Phase 1/2 Clinical Trial for Combination of IDE397 and AMG 193 in MTAP-Deletion Solid Tumors

by

IDE397 (MAT2A) and AMG 193 (PRMT5) combination being evaluated in an Amgen-sponsored Phase 1/2 clinical trial in MTAP-deletion solid tumors Potential first-in-class synthetic lethality combination targets mechanistically complementary nodes of the MTAP methylation pathway – MAT2A and PRMT5 Compelling preclinical anti-tumor efficacy presented at AACR 2023 with durable CRs for IDE397 / AMG 193 combination, … Read more

SprintRay Launches Ceramic-Infused 3D Printing Resins for High Performance Dentures

by

Features FDA 510(k) cleared High Impact Denture Base resin, the first ceramic-infused 3D printing material for denture bases, and certified biocompatible High Impact Denture Teeth resin Leverages proprietary, future-forward NanoFusion™ technology that suspends the optimal amount of ceramic, with minimal mixing, for superb denture strength and fracture resistance Introduces new, simplified treatment planning with SprintRay … Read more

WuXi Biologics Receives 2023 ISPE Facility of the Year Award for Operations

by

DUNDALK, Ireland, May 22, 2023 /PRNewswire/ — WuXi Biologics (“WuXi Bio”) (2269. HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that the International Society for Pharmaceutical Engineering (ISPE) has awarded the company a 2023 Facility of the Year Award (FOYA) in the Operations category. WuXi Biologics was recognized for using innovative … Read more

EVOLUTION RESEARCH GROUP, LLC REORGANIZES ITS CLINICAL SITE SERVICES BY THERAPEUTIC AREA PORTFOLIOS (TAPs) AND ANNOUNCES LEADERSHIP TEAM APPOINTMENTS

by

NEW PROVIDENCE, N.J., May 22, 2023 /PRNewswire/ — Evolution Research Group (ERG), a privately held, independent clinical development services organization focused on the execution of complex clinical programs has announced a reorganization of its clinical site operations to align under Therapeutic Area Portfolios (TAPs). The TAPs will be led by four industry veterans, Dr. Harold … Read more

Swiftsure Innovations Closes Seed Round

by

PASADENA, Canada, May 22, 2023 /PRNewswire/ — Swiftsure Innovations has closed today a $2.3 Million CAD Seed funding round. The round was led by Pelorus VC with participation from Sandpiper Ventures and pan-Canadian consortium MEDTEQ+ and several other pre-seed investors. “This funding provides us with capital to commercialize SwishKit, our innovative oral care solution for intubated … Read more

A.Menarini Diagnostics announces the release of the PRIME MDx platform

by

FLORENCE, Italy, May 22, 2023 /PRNewswire/ — A.Menarini Diagnostics S.r.l. is pleased to announce the commercial launch of its PRIME MDx platform: a sample-to-result, all-in-one, fully-automated molecular diagnostics platform for the processing of various testing portfolios through real-time PCR. The Covid-19 pandemic has significantly reshaped the molecular diagnostics market, pushing it in the direction of seamless automation, ease-of-use, … Read more

A.Menarini Diagnostics announces the release of the PRIME MDx platform

by

FLORENCE, Italy, May 22, 2023 /PRNewswire/ — A.Menarini Diagnostics S.r.l. is pleased to announce the commercial launch of its PRIME MDx platform: a sample-to-result, all-in-one, fully-automated molecular diagnostics platform for the processing of various testing portfolios through real-time PCR. The Covid-19 pandemic has significantly reshaped the molecular diagnostics market, pushing it in the direction of seamless automation, ease-of-use, … Read more